The loudness dependence of the auditory evoked potential (LDAEP) as a predictor of the response to escitalopram in patients with generalized anxiety disorder
The loudness dependence of the auditory evoked potential (LDAEP) as a predictor of the response to escitalopram in patients with generalized anxiety disorder
复制标题
DOI：
10.1007/s00213-010-2061-y
复制
发表时间：
2011-02-01
影响因子：
3.4
通讯作者：
Lee, Seung-Hwan
中科院分区：
文献类型：
--
作者：
Park, Young-Min;Kim, Do-Won;Lee, Seung-Hwan
听觉诱发电位（LDAEP）的响度依赖性已被认为是中枢神经系统兴奋性活动的潜在生物学标志。本研究旨在验证LDAEP可用于预测GAD患者对艾司西酞普兰的反应的假设。评估了汉密尔顿焦虑评定量表（HAM-A）、临床总体印象严重程度量表（CGI-S）和贝克焦虑量表（BAI）的评分。为了评估LDAEP，在开始用药前测量听觉事件相关电位。在五种刺激强度下计算峰-峰N1/P2振幅和电流源密度，并将LDAEP计算为线性回归斜率。采用标准化低分辨率脑电磁断层扫描（sLORETA）分析诱发电位的电流源密度。所有患者治疗前的LDAEP与第4、8周的CGI-S反应率、第8周的HAM-A反应率和BAI反应率均呈正相关。治疗8周后，sLORETA-LDAEPs与HAM-A应答率呈正相关。治疗前LDAEP较强的患者8周时的HAM-A和CGI应答率高于LDAEP较弱的患者。本研究显示，对艾司西酞普兰治疗有良好应答的GAD患者的特征是治疗前LDAEP较强。LDAEP的测量似乎为预测GAD患者的治疗反应提供了有用的临床信息。
The loudness dependence of the auditory evoked potential (LDAEP) has been proposed as a potential biological marker of central serotonergic activity. This study aimed to test the hypothesis that the LDAEP can be used to predict the response to escitalopram in patients with GAD.Twenty-five patients with GAD were recruited. Scores on the Hamilton Anxiety Rating Scale (HAM-A), Clinical Global Impression-Severity Scale (CGI-S), and Beck Anxiety Inventory (BAI) were evaluated. To evaluate the LDAEP, the auditory event-related potential was measured before beginning medication. Peak-to-peak N1/P2 amplitudes and current source densities were calculated at five stimulus intensities, and the LDAEP was calculated as the linear-regression slope. The current source densities of the evoked potentials were analyzed by standardized low-resolution brain electromagnetic tomography (sLORETA). The loudness dependence of the current densities (sLORETA-LDAEP) was also calculated.The pretreatment LDAEPs of all patients were positively correlated with the CGI-S response rates at 4 and 8 weeks, and with the HAM-A and BAI response rates at 8 weeks. The sLORETA-LDAEPs were positively correlated with the HAM-A response rates after 8 weeks of treatment. The HAM-A and CGI response rates at 8 weeks were higher in patients with a strong pretreatment LDAEP than in those with a weak LDAEP.The present study revealed that GAD patients with a favorable response to escitalopram treatment are characterized by a stronger pretreatment LDAEP. Measurement of the LDAEP appears to provide useful clinical information for predicting treatment responses in patients with GAD.